Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
Department
Adjust height of sidebar
KMap
Department
Obstetrics and Gynecology
10 active people
49 grants
Recent Grants
Developing Personalized Ovarian Cancer Risk Prediction through Circulating miRNA Biomarkers in 'Non-Genetic High-Risk' Women
2024
·
$250K
ovarian cancer risk,
circulating biomarkers,
mirna,
personalized prediction,
high-risk women
Advancing Native American Physicians in Medicine Through Partnerships for Recruiting, Retaining, and Supporting Native American Students
2024
·
$40K
native american health,
medical education,
diversity in medicine,
student support,
recruitment
Reestablishing Muscle Growth in the Growth Restricted Fetal Lamb
2023
·
$1.8M
fetal development,
muscle regeneration,
nutrition,
animal physiology,
growth restriction
Health Careers Opportunity Program
2023
·
$1.3M
healthcare,
public health,
education,
health disparities,
workforce development
The Role of Alpha1-Adrenergic Receptors Promoter Methylation in Cerebral Autoregulation in Fetus
2023
·
$763.7K
epigenetics,
neurodevelopment,
cerebrovascular regulation,
fetal development,
adrenergic receptors
Identification of Gene by Environment Interactions Influencing Genomic Risk Alleles Contributing to Equine Metabolic Syndrome
2023
·
$625K
genomics,
equine genetics,
metabolic syndrome,
gene-environment interactions,
risk alleles
A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tu
2023
·
$560.9K
ovarian cancer,
combination therapy,
platinum-resistant,
peritoneal cancer,
fallopian-tube cancer
Multicenter, Open-label, Phase 2 Study of Carboplatin Plus Mirvetuximab Soravtansine Followed by Mirvetuximab Soravtansine Continuation in Folate
2023
·
$419.4K
chemotherapy,
antibody-drug conjugate,
ovarian cancer,
clinical trial,
folate receptor
A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec followed by Platinum-doublet Chemotherapy and Bevacizumab Compared with Platinum-doublet Chemotherapy and Bevacizumab in Women
2023
·
$270.2K
clinical trials,
cancer treatment,
immunotherapy,
chemotherapy,
women's health
Alpha Adrenergic Methylation and Developmental Maturation of Cerebral Autoregulation in Ovine Preterm Fetus
2023
·
$153.5K
adrenergic regulation,
developmental maturation,
cerebral autoregulation,
preterm fetus,
methylation
Prevention of Placental Insufficiency Improves Beta-Cells Function
2022
·
$1.4M
placental insufficiency,
beta-cells function,
prevention,
research,
pregnancy
Prospective, Postmarket Study of the Desara? One Single Incision Sling vs. Desara? Blue Sling Implanted via the Transobturator Route for the Treatment of Women with Stress Urinary Incontinence
2022
·
$1.1M
urinary incontinence,
slingimplant,
transobturatorroute
A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without
2021
·
$339.8K
oncology,
immunotherapy,
clinical trial,
chemotherapy,
lung cancer
A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) Versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patien
2020
·
$406.1K
chemo-immunotherapy,
chemotherapy
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First- Line Treatment of BRCA Non-Mutated Advanced...
2020
·
$251.3K
chemotherapy,
immunotherapy,
maintenance therapy,
brca non-mutated
The OVAL Study: A Randomized, Controlled, Double-Arm, Open-Label, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Monotherapy for the Treatment of...
2019
·
$243.7K
clinical trials,
cancer treatment,
gene therapy,
paclitaxel combination
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line...
2016
·
$133.7K
ovarian cancer,
maintenance treatment,
hrd-positive,
niraparib
A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARB Inhibitor) in Subjects with Previously Untreated Stages III or IV
2016
·
$101.7K
chemotherapy,
parp inhibitors,
cancer treatment,
clinical trial,
oncology
A Multicentre Randomised Phase II Study of AZD1775 Plus Chemotherapy Versus Chemotherapy Alone in Patients with Platinum-Resistant TP53-Mutated Epithelial Ovarian, Fallopian Tube, or Primary...
2015
·
$295.3K
ovarian cancer,
chemotherapy,
tp53 mutation,
clinical trial,
drug combination
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platnum Maintenance Therapy for Participants with Recurrent, Platinum-Sensitive
2023
·
$217.6K
cancer therapy,
clinical trial,
pharmacology,
immunotherapy,
drug development
People
Amy Mitchell
Associate Professor
Chaur-Dong Hsu
Department Head
Celia Valenzuela
Associate Clinical Professor
Dipali Goyal
Research Professional II
Ravi Goyal
Professor
Heather Reed
Assistant Professor
Ilana Addis
Professor
John Heusinkveld
Associate Professor, Obstetrics and Gynecology - (Clinical Scholar Track)
Karen Lesser
Clinical Professor
Setsuko Chambers
Professor
Research expenses history
Funding support
7 funding agencies since 2020
